Pinilla Yudi T, Hoffmann Anton, Viehweg Maxim, Saison Nathanaël, Sambe Stravensky Terence Boussougou, Ndalembouly Ange Gatien Doumba, Ngossanga Barclaye, Awamu Florence, Adegnika Ayola Akim, Borrmann Steffen
Centre de Recherches Médicales de Lambaréné, Lambaréné BP 242, Gabon.
Institute for Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany.
Pathogens. 2025 May 6;14(5):453. doi: 10.3390/pathogens14050453.
is a neglected human malaria parasite despite its global distribution and propensity for persistent, sub-microscopic infections, which are associated with a mild but significant disease burden. Artemisinin-based therapies appear to be efficacious, but the susceptibility profiles of field isolates are largely unknown. We performed ex vivo assays with isolates collected from asymptomatic volunteers in Gabon. The mean concentrations required to inhibit 50% of growth (IC50) with chloroquine (n = 21), artesunate (n = 20), atovaquone (n = 21), and lumefantrine (n = 14) were 7.2 nM, 2.7 nM, 3.1 nM, and 7.4 nM, respectively. Our study provides novel data on the ex vivo susceptibility of to several key antimalarials, including the first dataset for atovaquone.
尽管其分布于全球且易于引发持续性亚显微感染（这种感染与轻度但显著的疾病负担相关），但它仍是一种被忽视的人类疟原虫。基于青蒿素的疗法似乎有效，但野外分离株的药敏谱在很大程度上尚不清楚。我们对从加蓬无症状志愿者身上采集的分离株进行了体外试验。用氯喹（n = 21）、青蒿琥酯（n = 20）、阿托伐醌（n = 21）和卤泛群（n = 14）抑制50%生长所需的平均浓度（IC50）分别为7.2 nM、2.7 nM、3.1 nM和7.4 nM。我们的研究提供了关于该疟原虫对几种关键抗疟药体外药敏性的新数据，包括阿托伐醌的首个数据集。
